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Abstract 
Several causes for primary ovarian insufficiency (POI) have been described, including iatrogenic and environmental 
factor, viral infections, chronic disease as well as genetic alterations. The aim of this review was to collect all the ge-
netic mutations associated with non-syndromic POI. All studies, including gene screening, genome-wide study and as-
sessing genetic mutations associated with POI, were included and analyzed in this systematic review. Syndromic POI 
and chromosomal abnormalities were not evaluated. Single gene perturbations, including genes on the X chromosome 
(such as BMP15, PGRMC1 and FMR1) and genes on autosomal chromosomes (such as GDF9, FIGLA, NOBOX, 
ESR1, FSHR and NANOS3) have a positive correlation with non-syndromic POI. Future strategies include linkage 
analysis of families with multiple affected members, array comparative genomic hybridization (CGH) for analysis of 
copy number variations, next generation sequencing technology and genome-wide data analysis. This review showed 
variability of the genetic factors associated with POI. These findings may help future genetic screening studies on 
large cohort of women.
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Introduction 
Primary ovarian failure (POF) or primary ovarian in-
sufficiency (POI) is defined as primary or secondary 
amenorrhea in women younger than 40 years of age 
with follicle stimulating hormone (FSH) ≥40 IU/L and 
estradiol levels ≤50 pg/mL (1-3). The anti-mullerian 
hormone (AMH) is another indicator of POI risk (2). 
Recently Venturella et al. (4) described a new method-
ology to quantify ovarian reserve combining clinical, 
biochemical and 3D-ultrasonographic parameters called 
ovAGE.
Several causes for POI have been described, includ-
ing iatrogenic and environmental factor, viral infec-
tions and chronic disease as well as genetic alterations 
(1, 5). Numerical defects of X chromosome, such as 
45,X and 47,XXX, are often associated with ovar-
ian dysgenesis and accelerated follicular atresia (1). 
Recently, single genes causing non-syndromic POI 
have been evaluated (6). The aim of this review was 
to collect all genetic mutations associated with non-
syndromic POI. 
Materials and Methods
Electronic databases were searched from inception of 
each database, until February 2018 (7). The research was 
conducted using MEDLINE, EMBASE, Web of Sciences, 
Scopus, ClinicalTrial.gov, OVID and Cochrane Library 
as electronic databases. Review of articles also included 
the abstracts of all references retrieved from the search. 
We used the following keywords and text words: “Ovar-
ian”, “Failure”, “POF”, “POI”, “Genetic”, “Genomic”, 
“Syndrome”, “Chromosomal”, “Premature”, “Primary” 
and “Infertility.” 
All studies assessing genetic mutations associated with 
non-syndromic POI, including mutations located in X and 
autosomal chromosomes, were analyzed. Syndromic POI 
and chromosomal abnormalities (e.g. numerical defects, 
X-structural abnormalities, X-autosome translocations 
and autosomal rearrangements) were not evaluated. Plei-
otropic single gene disorders (e.g. Fragile X syndrome), 
mitochondrial gene diseases (e.g. Perrault syndrome), and 
multiple malformation syndromes (e.g. cerebellar ataxia) 
were also excluded.
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Results
Single genes causing non-syndromic primary ovarian 
insufficiency
Many genes whose product is known playing a role in hu-
man folliculogenesis (candidate genes) have been studied (6).
Genes on the X chromosome
Bone morphogenetic protein 15 (BMP15) (Xp 11.2)
BMP15 is a member of the transforming growth factor 
(TGF) family involved in stimulating folliculogenesis. It 
promotes follicle maturation by regulating granulosa cell 
differentiation and proliferation (8). Evidences from ani-
mal models primarily suggested the possible involvement 
of BMP15 in pathogenesis of POI. Bmp15 knockout female 
mice presented subfertility and defective ovulation process-
es (9). Concerning human disease, the first evidence was 
reported in the 2004 (10).  They identified a heterozygous 
p.Y235C missense mutation in two POI patients, caused by 
decrease of granulosa cell proliferation through a dominant 
negative effect.  Many variants in BMP15 gene have been 
described in Caucasian, Indian and Chinese patients with 
POI (10-17). These variants in BMP15 lead to impaired di-
merization, reducing production of mature BMP15 active 
protein and subsequent defective granulosa cell signaling, 
in addition to increased follicle atresia.  
Progesterone receptor membrane component I (PGRMC1) 
(Xq22-q24)
PGRMC1 is a putative progesterone-binding membrane 
receptor, expressed in various tissues (18-22). Authors 
(21) have identified a mother and daughter with POI car-
rying an X-autosome translocation [t(X;11)(q24;q13)] 
and a sporadic missense mutation (p.H165R), in the cy-
tochrome b5 binding domain of PGRMC1. These vari-
ants are associated with lower levels of PGRMC1, and 
consequently ovarian cells apoptosis. Wang et al. (23) 
catalogued a different missense mutation (c.556C.T; p. 
P186S), however, more research is needed to establish as-
sociation of this variation with POI.
Androgen receptor (AR) (Xq12)
The AR gene is related with reproduction, as well as sex 
differentiation. AR is present in ovary, precisely in granulosa 
cells, and it is useful to follicles development. Shiina et al. 
(24) found that deficiency of AR in female mice may lead to 
a POI-like phenotype and dysregulation of many important 
genes involved in folliculogenesis. These results probably 
indicate that regular folliculogenesis need AR-mediated an-
drogen action. We reported two examples of mutations on 
AR gene linked with POI: CAG repeat length in exon 1 and 
two missense mutations (p.T650A and p.O658K) (25-30).
Premature ovarian failure, IB (POFIB) (Xq21.2)
POFIB is considered as a region codified by OMIM, 
located within the critical POI1 region.  In a patient with 
secondary amenorrhea (POI), this region was interrupted 
by a breakpoint in an X-autosome translocation. Lacombe 
et al. (31) proved linkage to Xq21 in a family having five 
patients with POI. A homozygous p.R329Q mutation was 
identified, leading to decreased ability to bind actin fila-
ments.
Dachshund family transcription factor 2 (DACH2) (Xq21.3)
DACH2 is located on Xq21.3 and involved in POI 
(32) with two missense mutations, p.R37L and p.F316S 
(33). 
Fragile X mental retardation I (FMRI) (Xq27.3)
FMR1 is an X-linked gene located at Xq27.3 and char-
acterized by CGG repeats in its 5’ untranslated region. 
Full mutation, consisting of >200 CGG repeats, is asso-
ciated with the fragile X-syndrome in male carriers, but 
not with POI. CGG repeats ranging from 55 to 199 are 
known as FMR1 premutation and recognized as com-
mon gene involved in POI. FMR1 premutations have 
been identified more frequently in POI patients having a 
positive family, compared to sporadic forms (34). FMR1 
premutations are more frequently identified in Caucasian 
patients with POI than general population (35). Com-
pared to Caucasian population, the prevalence of FMR1 
premutations is lower in Asian POI patients (36). Some 
studies indicate that there is no association between In-
termediate range of CGG repeats (41or 45-54 repeats) 
and POI (37). FMR1 protein is a RNA binding protein 
highly expressed in fetal ovary germ cells and granulosa 
cell. FMR1 premutations associate with decreased size 
of initial follicular pool (38-40).
Genes on autosomal chromosomes
Growth differentiation factor 9 (GDF9) (5q31.1)
As with BMP15, GDF9 is part of TGF gene family pre-
sented in oocytes. These characteristics make it an impor-
tant candidate gene for POI. New heterozygous variants 
have been found in European, Caucasian and Asian pa-
tients (41-43), but not in Japanese and New Zealand pop-
ulation (44, 45).  Norling et al. (46) performed high-res-
olution array comparative genomic hybridization (CGH) 
in 26 POI Swedish cases and discovered a partial GDF9 
gene duplication with 475 bp length. 
Folliculogenesis specific bHLH transcription factor (FIGLA) 
(2p13.3)
FIGLA, encodes an oocyte- specific, basic helix-loop-
helix (bHLH) transcription factor, which is necessary for 
the first stage of folliculogenesis. It regulates expression 
of zona pellucida genes. Three variants have been de-
scribed, by Zhao et al. (47), in 100 Chinese patients with 
POI, including missense mutation in two women, deletion 
of p.G6fsX66 in one woman and deletion p.140delN in 
another woman. The Deletion of p.G6fsX66 may cause 
POI through a mechanism of haploinsufficiency, while 
Genetics of Non-Syndromic POI
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the deletion of p.140delN may induce impaired heterodi-
merization. Tosh et al. (48) also identified an intronic vari-
ant in 209 Indian patients with POI. 
New ovary homeobox gene (NOBOX) (7q35)
NOBOX is an ovary homeobox gene involved in first stag-
es of folliculogenesis. Rajkovic et al. (49) identified NO-
BOX role, using knockout mouse models. In female mice, 
they determined fibrous tissues replacing follicles, caus-
ing similar phenotype to non-syndromic ovarian failure. 
Lechowska et al. (50) identified that NOBOX deficiency 
may lead to POI through a disorder caused due to com-
munication between somatic cells and oocytes during em-
bryonic development. This results in anomalous junctions 
between joined oocytes within syncytial follicles. Several 
NOBOX mutations have been detected in Caucasian POI 
patients (51-53). For instance, p.R355H mutation associ-
ates with a decrease in NOBOX DNA binding activity and 
a dominant negative effect.  No NOBOX variant has been 
found in Chinese women with POI (54).
Nuclear receptor subfamily 5, group A, member I (NR5AI): 
Steroidogenic factor1 (SF1) (9q33)
NR5A1, SF1, is a nuclear receptor involved in early go-
nadal differentiation. NR5A1 modulates the transcription 
of genes implicated in steroidogenesis such as AMH, nu-
clear receptor subfamily 0, group B, member 1 (DAX1), 
CYP11A, steroidogenic acute regulatory protein (StAR), 
CYP17A1, CYP19A1 and INHA. N5RA1 knockout in 
mouse granulosa cells induced hypoplastic ovaries, re-
duced number of oocytes and infertility. NR5A1 muta-
tions have been identified by Lourenco et al. (55) in four 
families with history of POI and in 2/25 women with 
sporadic POI. These mutations, not identified in control 
patients, were associated with altered transactivation ac-
tivity of factors involved in follicle growth. In a study in-
cluding 356 Dutch patients with POI, nine different muta-
tions were determined in coding regions of NR5A1 (56). 
Jiao et al have identified Py5D mutation, as a non-domain 
region, in Chinese women with POI. 
Estrogen receptor 1 (ESR1) (6q25.1)
ESR1 gene is one of the two estrogen receptor subtypes. 
It has been considered as a potential candidate gene for POI 
(57). ESR1 knockout mice models showed an early loss 
of fertility due to the impaired follicles maturation. Qin 
et al. (58) analyzed 41 single nucleotide polymorphisms 
(SNPs) in 400 cases and 800 women controls. They found 
one SNPs related to POI in ESR1 (rs2234693) in Korean 
and Dutch women. They also identified two novel SNPs 
in HK3 and BRSK1 (rs2278493 and rs12611091, respec-
tively), probably involved in POI pathogenesis.
FSH receptor (FSHR) (2p21-p16)
FSH/FSHR signaling has an important role in regular 
gonadal function. A study, composed of 75 patients with 
hypergonadotrophic ovarian dysgenesis and primary or 
secondary amenorrhea cases, discovered homozygous 
mutations (59-61). These mutations are common (0.96%) 
in Finnish women, but rare in the other populations (13, 
62-70).
TGF, beta receptor III (TGFBR3) (1p33-p32)
Human TGFBR3 is located at 1p33-p32 and translates 
the TGF-beta type III receptor. In Chinese women with 
idiopathic POI, two missense variants, p.E459G and 
p.P825L were identified. The third one, p.P775S, was dis-
covered in an Indian POI case. 
G protein-coupled receptor 3 (GPR3) (1p36.1-p35)
GPR3 gene is an element of the G protein coupled re-
ceptor family. In Gpr32/2 mice, higher quantity of the oo-
cytes, in antral follicles, quickly restarted meiosis. Similar 
variant (c.135G.A; p.V45V) was discovered in one Chi-
nese woman. 
Wingless-type MMTV integration site family, member 4 
(WNT4) (1p36.23-p35.1)
WNT4 translates a secreted extracellular signaling pro-
tein which plays a role in female sex differentiation. 
Inhibins (INH): Inhibin, alpha (INHA) (2q35), Inhibin, 
beta A (INHBA) (7p15-p13), Inhibin, beta B (INHBB) 
(2cen-q13)
INH is a member of TGF-b family. In New Zealand 
(7%), Indian (11.2%) and Italian (4.5%) women with POI 
a common missense variation c.769G.A (p.A257T) was 
found in the INHA gene. Regarding INHBA, new mis-
sense variations were found only in Indian POI women. 
Causative variation in INHBA and INHBB genes has not 
been found yet.
POU class 5 homeobox 1 (POU5FI) (6p21.31)
In NOBOX gene knockout mice, POU5F1 reproduction 
factor gene is significantly down-regulated, making it a 
possible aspirant gene for POI. A study found one non-
synonymous mutation (p.P13T) in 175 Chinese women 
with POI.
Class 5 homeobox MutS homolog 4 (MSH4) (1p31) and 
MSH5 (6p21.3)
MSH4 (1p31) and MSH5 (6p21.3) are members of mam-
malian DNA mismatch repair genes family. Mouse model 
carrying an inactivating MSH4 mutation in the germ line, 
identified a severe disruption of meiosis in Msh4 mutant 
females and males. Furthermore, failure of the chromo-
some pairing in oocytes caused apoptosis increase, loss 
of oocyte pool and ovarian structures. A heterozygous 
mutation p.P29S in the MSH4-binding domain of MSH5 
in Caucasian patients. Guo et al. (36), using whole ex-
ome sequencing in a Chinese pedigree with POI, identi-
fied a homozygous missense mutation (p.D487Y) in the 
MSH5 gene of two sisters with POI. In addition, POI phe-
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notype was determined in mice carrying the homologous 
mutation.
Cbp/p300-interacting transactivator, with Glu/Asp-rich car-
boxy-terminal domain, 2 (CITED2) (6q23.3)
CITED2 gene encodes a protein inhibiting transactiva-
tion of HIF1A-induced genes. CITED2 mutations may 
lead to idiopathic POF. Fonseca et al. (30) analyzed 139 
patients with POI and 290 controls. They identified a mis-
sense mutation p.P202T in CITED2 of one case. More 
studies are needed to identify the role of CITED2 muta-
tions in POI pathogenesis.
Spermatogenesis and oogenesis specific basic helix-loop-he-
lix transcription factor I (SOHLHI) (9q31.3) and SOHLH2 
(13q13.3)
SOHLH1 and SOHLH2 are only expressed in primor-
dial follicles and they encode testis-specific transcription 
factors. They are needed for spermatogenesis, oogenesis 
and early folliculogenesis.  Sohlh2 knockout adult fe-
male mice are infertile, since differentiation of the oocyte 
during early oogenesis is compromised and oocytes are 
quickly lost. 
Phosphatase and tensin homolog (PTEN) (10q23.3)
PTEN gene, located on chromosome 10q23.3, encodes 
protein which negatively regulates intracellular levels of 
PI3K and consequently AKT/PKB signaling pathway in 
cells. It has been found essential maintenance of dorman-
cy of primordial follicles. In mice with PTEN deficiency, 
the entire pool of primordial follicles was prematurely ac-
tivated and early depleted. 
Nanos homolog 1, 2, 3 (Drosophilia): NANOSI (10q23.11), 
NANOS2 (19q13.32), NANOS3 (19q13.13)
NANOS gene belongs to a family needed for pri-
mordial germ cell (PGC) evolution and conservation. 
Three homologs of this molecule have thus far been 
determined: NANOS1, NANOS2 and NANOS3. NA-
NOS2 defect solely cause spermatogonia failure, while 
defective PGC conservation in both males and females 
with NANOS3 deficiency was observed. NANOS3 vari-
ants have been studied in 80 Chinese and 88 Cauca-
sian POI patients. No causative variant was detected 
in coding exons, while a different study found a hypo-
thetically important heterozygous mutation (c.457C.T; 
p.R153W). In addition, new homozygous variation 
(c.358G.A; p.E120K) was discovered in two sisters 
with POI. 
Cyclin-dependent kinas inhibitor IB (CDKNIB) (12p13.1-p12)
CDKN1B, also known as P27 or KIP1, translates an 
inhibitor involved in growth and differentiation of sev-
eral tissue. It is responsible for follicle atresia. Authors, 
showed early follicle depletion in CDKN1B knockout 
mice. 
Anti-mullerian hormone receptor, type II (AMHR2) (12q13)
AMHR2 translates an AMH receptor. It has a central part 
in the conservation and growth of reproductive organs in 
humans (6). Studies found a polymorphism (c.-482 A.G; 
rs2002555) in AMHR2 of some populations, but not in 
the others (58). Recently, two new missense variations in 
a group of Chinese women with POI was noted by Qin et 
al. (58).
Forkhead box protein L2 (FOXL2) (3q23)
FOXL2 belongs to forkhead family of transcription fac-
tors, expressed in mammalian undifferentiated granulosa 
cells. It may play a role in fertility conservation. FOXL2 
knockout mouse models presented an early activation and 
decrease of primordial follicles. Moreover, one study re-
cently identified that FOXL2 is essential for regulation of 
AMH. Three FOXL2 mutations have been found in almost 
5% of non-syndromic POI patients, including c.772T>A 
(p. Tyr258Asp), c.661_690del (p.Ala221_Ala230del) and 
c.560G>A (p.Gly187Asp). 
Forkhead box 03 (FOX03) (6q21)
FOXO3 gene, located at 6q21, belongs to the forkhead 
family of transcription factors. FOXO3 is involved in 
oocyte quiescence. It suppresses initiation of follicular 
maturation and controls the rate of utilization of the re-
productive potential. FOXO3 null mice presented an early 
global activation of primordial follicles, until a premature 
depletion of the primordial oocyte pool. Several FOXO3 
variants have been identified in different ethnic groups 
with different frequency. 
Forkhead box 01 (FOX01) (13q14.1)
FOXO1, belonging to forkhead family of transcription 
factors, may be involved in follicular steroidogenesis and 
plays a role in follicle development by controlling granu-
losa cell proliferation, apoptosis and differentiation. In 60 
patients with POI from New Zealand and Slovenia two 
variants have been found. These variants included one 
missense mutation, and one 5’ UTR mutation (p.P84L and 
c.-30C.T, respectively).
The Wilms tumor 1 (WT1) gene (11p13)
WT1 gene is translated to a transcription factor ex-
pressed in granulosa cells. Variations of this gene lead to 
defects in granulosa cell polarity, which could explain the 
origin of POI and POI phenotype in knockout mice. 
The Splicing Factor 1 (SF1) gene (11q13.1)
SF1 has a significant role in ovarian development and 
it appears to cause POI in Tunisian women by reducing 
estradiol levels.
Spalt-like transcription factor 4 (SALL4) (20q13.2)
SALL4 encodes a zinc finger transcription factor which 
Genetics of Non-Syndromic POI
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plays role in the developing limbs and motor neurons. 
SALL4 might also be involved in conferring totipotency 
on oocytes. So, 100 Han Chinese women with non-syn-
dromic ovarian failure were screened and two variants 
were identified in this gene, including p.Val181Met and 
p.Thr817Ala. 
Meiotic protein covalently bound to DSB (SP011) (20q13.31)
SPO11 encodes a protein which is essential for forma-
tion of double stranded breaks (DSBs) (or initiation of 
meiotic DSBs). It is also required for the chromosome 
segregation. Infertility has been observed in Spo11 knock-
out mice due to impaired meiosis and depletion of oo-
cytes. 
DNA meiotic recombinase I (DMCI) (22q13.1)
DMC1 encodes a member of the recombinases family 
(also called DNA strand-exchange proteins). Recombi-
nases are essential in repairing breaks of double-strand 
DNA. 
Genome-wide studies in primary ovarian insufficiency
The candidate gene approach and cytogenetic studies 
have provided some important results so far. Recently, 
new strategies have been performed for identifying new 
genes and unknown pathways associated with POI de-
velopment. These strategies include linkage analysis in 
families with multiple affected patients, array-CGH for 
analysis of copy number variants (CNVs), genome-wide 
association (GWA) studies (GWAS), genome-wide se-
quencing of exomes (WES) and the whole genome se-
quencing (WGS) as well as the next generation sequenc-
ing (NGS) (6).
Genome-wide association studies 
In genetics, a GWAS consists of the analysis of a ge-
nome-wide set of genetic variants to discover their asso-
ciation with a trait. Especially, GWASs focus on SNPs. 
GWA studies use high-throughput genotyping technolo-
gies to investigate the entire genome and common SNPs 
assay, without any prior hypotheses regarding the mecha-
nism or biological pathways. Then, this analysis consists 
of studying SNPs in affected and control women. 
Thanking GWAS, several potentially POI related loci 
were identified in Chinese, Korean, and Dutch women, 
but no interesting finding was confirmed by replicating 
these studies. The major limitation of GWAS is lack of 
statistical power, due to population proportions and sam-
ple size. POI is actually a rare disease, so it could be dif-
ficult to increase the sample size.
Genome-wide association studies based family linkage 
analysis 
Some GWAS studies also showed a dominant pattern of 
inheritance. A large consanguineous Middle-Eastern fam-
ily with POI, presenting an autosomal recessive pattern 
of inheritance, was subject of GWA. They identified two 
regions including 7p21.1-p15.3 and 7q21.3-q22.2. 
Genome-wide association studies based on age of men-
opause
A new strategy to identify genetic mechanism involved 
in POI might consist of using evidences from shared ge-
netic susceptibility natural menopause or early meno-
pause women. Studies have identified a significant asso-
ciation between POI and three SNPs including rs2278493 
in hexokinase 3 (HK3), rs2234693 in estrogen receptor 1 
(ESR1) and rs12611091 in BR serine/threonine kinase 1 
(BRSK1) (6). 
Copy number variants
CNVs are a structural variants involving DNA regions 
>1 kb. They consist of alterations in the copy number of 
specific regions such as deletions and duplications. They 
can be either inherited or spontaneously arisen de novo, 
leading to phenotypic variations and disease. Recently, 
array-CGH has been used to search CNVs potentially 
involved in POI. Studies have identified eight statisti-
cally significant different CNVs in chromosomal regions 
(1p21.1, 5p14.3, 5q13.2, 6p25.3, 14q32.33, 16p11.2, 
17q12 and Xq28) of five genes playing role in reproduc-
tion, includingDynein axonemal heavy chain 5 (DNAH5), 
NLR family apoptosis inhibitory protein (NAIP), dual 
specificity phosphatase 22 (DUSP22), nuclear protein 1 
transcriptional regulator (NUPR1) and AKT serine/threo-
nine kinase 1 (AKT1). 
Ledig et al. (13) performed array-CGH analysis in 74 
German patients with POI and identified 44 rearrangements 
(deletions and insertions) through several genes involved 
in meiosis, DNA repair and folliculogenesis. Seventeen 
novel microduplications and seven novel microdeletions, 
six of which were located in the coding regions of 8q24.13, 
10p15-p14, 10q23.31, 10q26.3, 15q25.2 and 18q21.32 have 
been identified. Two novel microdeletions were discovered 
to cause haploinsufficiency for SYCE1 and CPEB1 genes 
playing a role in ovarian failure in knockout mouse models. 
In 2014, Norling et al. (46) performed a case-control study. 
They used arrayCGH to identify CNVs in 26 POI patients. 
Eleven unique CNVs were found in 11 patients, including 
a tandem duplication in part of the GDF9 gene promoter 
region, known as probable causative gene for POI. Further 
studies in much larger POI samples are needed to identify 
novel CNVs and to discern the utility of array-CGH in re-
placing conventional karyotyping. 
Whole exome sequencing 
WES allows simultaneous analysis of base pairs across 
the entire exome. This was traditionally defined as the se-
quence encompassing all exons of protein coding genes in 
the genome. Six WES was performed in non-syndromic 
inherited POI. It has been indicated that majority of the 
candidate genes play role in meiosis and DNA repair, in 
this study (Table 1). 
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Table 1: Identified genes using WES associated with non-syndromic inherited 
POI
Abbreviation Genes
STAG3 Stromal antigen 3
SYCE1 Synaptonemal complex central element
eIF4ENIF1 Eukaryotic translation initiation factor 4E 
nuclear import factor
CLPP Caseinolytic mitochondrial matrix peptidase 
proteolytic subunit
C10ORF2 Chromosome 10 open reading frame 2  
HFM1 ATP-dependent DNA helicase homolog
MCM8 and MCM9 Minichromosome maintenance complex 
component 8 and 9
LARS2 Leucyl-tRNA synthetase 2, mitochondria; 
C10orf2
HSD17B4 Hydroxysteroid (17-beta) dehydrogenase 4
WES; Whole exome sequencing and POI; Primary Ovarian Insufficiency.
Whole genome sequencing and next generation se-
quencing
NGS has revolutionized genomic research. Thanks 
to NGS an entire human genome can be sequenced in 
a single day and new molecular players in POI can be 
identified.  Fonseca et al. (30) performed a retrospec-
tive case-control cohort study including 12 patients with 
non-syndromic POI and 176 controls. NGS was used to 
sequence complete coding regions of 70 candidate genes 
in POI patients and mutations in ADAMT19, BMPR2 and 
LHCG were identified. 
Discussion
This review includes almost all genetic abnormalities 
and genes linked with non-syndromic POI. This exhib-
its the importance and variability of genetic elements 
involved in POI genesis and identified by different tech-
niques. Different conclusion can be made based on our 
review. First, several genes come out as POI candidates, 
but only a little part of them have been established un-
equivocally causative factor, by functional tests. Second, 
remarkable differences in frequency exist among differ-
ent ethnic groups. New studies with a large sample sizes 
should more imply disparate ethnic groups. Moreover, in-
teractions between gene-gene and protein-protein are not 
yet entirely clear. Recent and future advances in sequenc-
ing techniques will help find other novel genes involved 
in POI. Finally, discovering the pathogenesis and molecu-
lar bases of POI is useful not only to understand the ovar-
ian physiology, but also to improve genetic and fertility 
counseling. Once new variants are found, they can help 
prognosticate the age of menopause. In future, findings 
from this review may help large genetic screening studies 
on infertility and may help women plan their fertility.
Conclusion
This review showed variability of the genetic factors as-
sociated with POI. These findings may help future genetic 
screening studies on large cohort of women.
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